ATE191922T1 - Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen - Google Patents
Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungenInfo
- Publication number
- ATE191922T1 ATE191922T1 AT95936023T AT95936023T ATE191922T1 AT E191922 T1 ATE191922 T1 AT E191922T1 AT 95936023 T AT95936023 T AT 95936023T AT 95936023 T AT95936023 T AT 95936023T AT E191922 T1 ATE191922 T1 AT E191922T1
- Authority
- AT
- Austria
- Prior art keywords
- pcna
- binding
- substances
- waf
- determination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9422175A GB9422175D0 (en) | 1994-11-03 | 1994-11-03 | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof |
PCT/GB1995/002583 WO1996014334A1 (en) | 1994-11-03 | 1995-11-03 | IDENTIFICATION OF THE p21WAF1-PCNA INTERACTION SITE AND THERAPEUTIC APPLICATIONS THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE191922T1 true ATE191922T1 (de) | 2000-05-15 |
Family
ID=10763826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95936023T ATE191922T1 (de) | 1994-11-03 | 1995-11-03 | Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen |
Country Status (8)
Country | Link |
---|---|
US (1) | US6242201B1 (de) |
EP (1) | EP0789711B1 (de) |
JP (1) | JPH10509312A (de) |
AT (1) | ATE191922T1 (de) |
CA (1) | CA2203909A1 (de) |
DE (1) | DE69516416T2 (de) |
GB (1) | GB9422175D0 (de) |
WO (1) | WO1996014334A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2644495A (en) * | 1994-05-24 | 1995-12-18 | Baylor College Of Medicine | Mimetics of senescent cell derived inhibitors of dna synthesis |
GB9509557D0 (en) * | 1995-05-11 | 1995-07-05 | Univ Dundee | PCNA binding substance |
US6962792B1 (en) | 1996-05-08 | 2005-11-08 | Cyclacel Limited | Methods and means for inhibition of Cdk4 activity |
SE520392C2 (sv) | 1996-09-27 | 2003-07-01 | Creative Peptides Sweden Ab C | Specifika peptider för behandling av diabetes mellitus |
FR2754822B1 (fr) * | 1996-10-18 | 1998-11-27 | Rhone Poulenc Rorer Sa | Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations |
ATE374369T1 (de) | 1997-03-14 | 2007-10-15 | Crusade Lab Ltd | Verfahren zur erkennung von regulatoren des zellzyklus |
US6489305B1 (en) * | 1998-05-08 | 2002-12-03 | Canji, Inc. | Methods and compositions for the treatment of ocular diseases |
EP0974649A1 (de) | 1998-06-22 | 2000-01-26 | Universität Zürich | Screening-System |
SG101524A1 (en) * | 1999-05-21 | 2004-01-30 | Matsushita Electric Ind Co Ltd | Optical disk, and recording/reproducing apparatus and recording method for optical disk |
GB9928323D0 (en) * | 1999-11-30 | 2000-01-26 | Cyclacel Ltd | Peptides |
US7449544B2 (en) | 1999-11-30 | 2008-11-11 | Cyclacel Limited | p21 peptides |
GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
US7259232B1 (en) * | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
US6924095B2 (en) * | 2001-08-15 | 2005-08-02 | The Regents Of The University Of California | Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
EP1687331A1 (de) * | 2003-10-20 | 2006-08-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tyrosinphosphorylierung von cdk-inhibitorproteinen der cip/kip-familie |
US7465442B2 (en) * | 2003-11-24 | 2008-12-16 | Canji, Inc. | Reduction of dermal scarring |
GB0410498D0 (en) * | 2004-05-11 | 2004-06-16 | Cyclacel Ltd | Crystal |
MX2007002169A (es) | 2004-08-27 | 2007-08-14 | Cyclacel Ltd | Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes. |
GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
WO2011104309A1 (en) * | 2010-02-24 | 2011-09-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compounds for the treatment of inflammation and neutropenia |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2662698A1 (fr) | 1990-06-05 | 1991-12-06 | Centre Nat Rech Scient | Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite. |
US5596079A (en) | 1991-12-16 | 1997-01-21 | Smith; James R. | Mimetics of senescent cell derived inhibitors of DNA synthesis |
US5302706A (en) | 1991-12-16 | 1994-04-12 | Baylor College Of Medicine | Senescent cell derived inhibitors of DNA synthesis |
JP3485186B2 (ja) | 1992-10-16 | 2004-01-13 | コールド・スプリング・ハーバー・ラボラトリー | サイクリン複合体の転位およびそれに関連する使用 |
JP3822232B2 (ja) | 1993-08-30 | 2006-09-13 | ベイラー・カレッジ・オブ・メディシン | 老化細胞由来dna合成阻害因子 |
WO1995013375A1 (en) | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Tumor suppressor waf1 |
AU2644495A (en) | 1994-05-24 | 1995-12-18 | Baylor College Of Medicine | Mimetics of senescent cell derived inhibitors of dna synthesis |
EP0850066A1 (de) | 1995-07-20 | 1998-07-01 | Worcester Foundation For Biomedical Research, Inc. | Verfahren zur selektiven abtötung oder hemmung des wachstums von zellen, welche das waf1-gen exprimieren |
-
1994
- 1994-11-03 GB GB9422175A patent/GB9422175D0/en active Pending
-
1995
- 1995-11-03 AT AT95936023T patent/ATE191922T1/de not_active IP Right Cessation
- 1995-11-03 JP JP8515137A patent/JPH10509312A/ja active Pending
- 1995-11-03 DE DE69516416T patent/DE69516416T2/de not_active Expired - Fee Related
- 1995-11-03 WO PCT/GB1995/002583 patent/WO1996014334A1/en active IP Right Grant
- 1995-11-03 CA CA002203909A patent/CA2203909A1/en not_active Abandoned
- 1995-11-03 EP EP95936023A patent/EP0789711B1/de not_active Expired - Lifetime
- 1995-11-03 US US08/817,895 patent/US6242201B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6242201B1 (en) | 2001-06-05 |
CA2203909A1 (en) | 1996-05-17 |
EP0789711B1 (de) | 2000-04-19 |
EP0789711A1 (de) | 1997-08-20 |
DE69516416D1 (de) | 2000-05-25 |
JPH10509312A (ja) | 1998-09-14 |
WO1996014334A1 (en) | 1996-05-17 |
GB9422175D0 (en) | 1994-12-21 |
AU3811395A (en) | 1996-05-31 |
AU694574B2 (en) | 1998-07-23 |
DE69516416T2 (de) | 2000-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE191922T1 (de) | Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen | |
RU95115239A (ru) | Аналог эритропоэтина | |
BR0213786A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
EA199801044A1 (ru) | Модуляторы регенерации тканей | |
DE69434926D1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
DE69725293D1 (de) | N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität | |
BR9408025A (pt) | Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases | |
CY1111120T1 (el) | Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση | |
DE69534165D1 (de) | Adenovirus mit glutathion peroxydate gene | |
BR0207638A (pt) | Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células | |
BG106051A (en) | MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENING | |
EA200001124A1 (ru) | Способ генной терапии | |
DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
ES549115A0 (es) | Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores | |
DE69607034D1 (de) | Pcna bindende substanz | |
SE8901342L (sv) | Biologiska material, foerfaranden foer framstaellning av biologiska material samt foer anvaendning av saadana material i terapi | |
CA2370098A1 (en) | Human beta-trcp protein | |
EA200401390A1 (ru) | N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения | |
EA199901061A1 (ru) | Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии | |
ATE216707T1 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
ATE300554T1 (de) | Bindegewebe-wachstumsfaktor 3. | |
BR0013665A (pt) | Uso de uma proteìna histacalina, composição farmacêutica, e, método de tratar ou impedir conjuntivite | |
DE69631624D1 (de) | Antikörper gegen menschliches restrictin | |
TR200002611T2 (tr) | Beta-lipotropin ve kullanımları | |
DE69825307D1 (de) | Verwendung von protein h als zytostattischer wirkstoff |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |